Stock IMMU MENDUS AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Mendus AB

Equities

IMMU

SE0005003654

Biotechnology & Medical Research

Real-time Estimate Cboe Europe
Other stock markets
 08:41:24 08/05/2024 BST 		5-day change 1st Jan Change
0.455 SEK -0.98% Intraday chart for Mendus AB -0.75% -11.85%
04-16 Mendus AB Announces Board Changes CI
03-27 Mendus AB Announces Ethics Committee Approval for the AMLM22-CADENCE Trial with Lead Product Vididencel in AML CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 970.5 1,230 854.4 480.6 451.4 462.8 - -
Enterprise Value (EV) 1 674.6 1,081 735.8 490.7 331.5 403.5 271 -7.195
P/E ratio -7.01 x -6.32 x -5.87 x -3.44 x -2.38 x -3.83 x 3.68 x -
Yield - - - - - - - -
Capitalization / Revenue - - 27,562 x 142 x 15.2 x - 1.75 x -
EV / Revenue - - 23,735 x 145 x 11.2 x - 1.03 x -
EV / EBITDA -5.1 x - -5.66 x -3.73 x -3.69 x -3.13 x 2.03 x 0.19 x
EV / FCF - - -5.28 x -4.03 x -1.88 x -4.58 x 0.69 x 0.19 x
FCF Yield - - -18.9% -24.8% -53.3% -21.8% 144% 528%
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 92,258 166,167 199,401 199,401 863,148 1,007,192 - -
Reference price 2 10.52 7.400 4.285 2.410 0.5230 0.4595 0.4595 0.4595
Announcement Date 18/02/20 18/02/21 17/02/22 17/02/23 14/02/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - 0.031 3.375 29.61 - 264 -
EBITDA 1 -132.3 - -130.1 -131.5 -89.78 -128.7 133.4 -38
EBIT 1 -132.3 -86.03 -130.1 -133.7 -100.6 -129.6 132.5 -38
Operating Margin - - -419,677.42% -3,961.04% -339.88% - 50.2% -
Earnings before Tax (EBT) 1 -134 -89.25 -133.4 -138.8 -101.6 -130 132 -38
Net income 1 -134 -89.25 -133.4 -138.8 -101.6 -130 132 -38
Net margin - - -430,354.84% -4,112.15% -343.16% - 50.01% -
EPS 2 -1.500 -1.170 -0.7300 -0.7000 -0.2200 -0.1200 0.1250 -
Free Cash Flow 1 - - -139.4 -121.7 -176.6 -88 390 -38
FCF margin - - -449,658.06% -3,604.62% -596.41% - 147.73% -
FCF Conversion (EBITDA) - - - - - - 292.31% -
FCF Conversion (Net income) - - - - - - 295.37% -
Dividend per Share - - - - - - - -
Announcement Date 18/02/20 18/02/21 17/02/22 17/02/23 14/02/24 - - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - 10.2 - - - -
Net Cash position 1 296 149 119 - 120 59.3 192 470
Leverage (Debt/EBITDA) - - - -0.0775 x - - - -
Free Cash Flow 1 - - -139 -122 -177 -88 390 -38
ROE (net income / shareholders' equity) - - -20.2% -23.7% -16.7% -20% 46% -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 1 - - 1.36 12.3 10.2 - - -
Capex / Sales - - 4,390.32% 365.16% 34.48% - - -
Announcement Date 18/02/20 18/02/21 17/02/22 17/02/23 14/02/24 - - -
1SEK in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MENDUS AB Stock Mendus AB
-11.85% 42.8M
MODERNA, INC. Stock Moderna, Inc.
+21.74% 46.4B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.97% 41.75B
LONZA GROUP AG Stock Lonza Group AG
+49.11% 41.37B
CELLTRION, INC. Stock Celltrion, Inc.
-3.52% 29.71B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.12% 26.01B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-19.37% 19.52B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+31.18% 12.43B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-0.04% 12.13B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.39% 12.18B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. IMMU Stock
  4. Financials Mendus AB